[go: up one dir, main page]

CY1120348T1 - Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων - Google Patents

Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Info

Publication number
CY1120348T1
CY1120348T1 CY20181100630T CY181100630T CY1120348T1 CY 1120348 T1 CY1120348 T1 CY 1120348T1 CY 20181100630 T CY20181100630 T CY 20181100630T CY 181100630 T CY181100630 T CY 181100630T CY 1120348 T1 CY1120348 T1 CY 1120348T1
Authority
CY
Cyprus
Prior art keywords
disease
suppliers
terrain
inhibitors
aryl
Prior art date
Application number
CY20181100630T
Other languages
English (en)
Inventor
Emily M. Stocking
Wolfgang Wrasidlo
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120348(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of CY1120348T1 publication Critical patent/CY1120348T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ορισμένες ενώσεις αμιδίων ετεροαρυλίου, φαρμακευτικές συνθέσεις περιέχοντας αυτές, και μεθόδους χρήσεις αυτών, που συμπεριλαμβάνουν μεθόδους για πρόληψη, αντιστροφή, επιβράδυνση ή αναστολή συσσωμάτωσης πρωτεϊνών, και μεθόδους αγωγής παθήσεων που συσχετίζονται με συσσωμάτωση πρωτεϊνών, που συμπεριλαμβάνουν νευροεκφυλιστικές παθήσεις όπως είναι η νόσος του Πάρκινσον, η νόσος του Αλτσχάϊμερ, η πάθηση σωμάτων Lewy, η νόσος του Πάρκινσον με άνοια, η κροταφομετωπιαία άνοια, η Νόσος του Χάντινγκτον, η αμυοτροφική πλευρική σκλήρυνση, και η ατροφία πολλαπλών συστημάτων, και ο καρκίνος και το μελάνωμα.
CY20181100630T 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων CY1120348T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
CY1120348T1 true CY1120348T1 (el) 2019-07-10

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20181100630T CY1120348T1 (el) 2014-01-29 2018-06-15 Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100682T CY1123374T1 (el) 2014-01-29 2020-07-24 Αμιδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων

Country Status (38)

Country Link
US (3) US9738635B2 (el)
EP (2) EP3348556B1 (el)
JP (2) JP6619741B2 (el)
KR (1) KR102383038B1 (el)
CN (2) CN111039939B (el)
AP (1) AP2016009347A0 (el)
AU (1) AU2015211119B2 (el)
BR (2) BR112016017344B1 (el)
CA (1) CA2937967C (el)
CL (1) CL2016001918A1 (el)
CR (1) CR20160394A (el)
CY (2) CY1120348T1 (el)
DK (2) DK3099684T3 (el)
EA (1) EA032374B1 (el)
EC (1) ECSP16070327A (el)
ES (2) ES2808978T3 (el)
HK (1) HK1231470A1 (el)
HR (2) HRP20180813T1 (el)
HU (2) HUE050964T2 (el)
IL (1) IL246987B (el)
LT (2) LT3099684T (el)
ME (1) ME03800B (el)
MX (1) MX2016009896A (el)
MY (1) MY187450A (el)
NZ (1) NZ722487A (el)
PE (1) PE20161393A1 (el)
PH (1) PH12016501493B1 (el)
PL (2) PL3348556T3 (el)
PT (2) PT3348556T (el)
RS (2) RS60547B1 (el)
SA (1) SA516371579B1 (el)
SG (1) SG11201606108RA (el)
SI (2) SI3099684T1 (el)
SM (2) SMT202000376T1 (el)
TR (1) TR201809440T4 (el)
UA (1) UA118209C2 (el)
WO (1) WO2015116663A1 (el)
ZA (1) ZA201605246B (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60547B1 (sr) 2014-01-29 2020-08-31 UCB Biopharma SRL Heteroaril amidi kao inhibitori proteinske agregacije
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
ES2918048T3 (es) * 2017-01-26 2022-07-13 UCB Biopharma SRL Derivados de alcoxi bis-heteroarilo como moduladores de la agregación de proteínas
EP3573986B1 (en) * 2017-01-26 2021-05-26 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation
AU2018212436A1 (en) 2017-01-26 2019-07-25 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
US11180518B2 (en) * 2017-05-12 2021-11-23 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
EP3664822A4 (en) * 2017-08-04 2021-07-07 Axial Therapeutics, Inc. MICROBIAL INDUCED AMYLOID FORMATION INHIBITORS
WO2019089640A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
CN118488951A (zh) 2021-12-27 2024-08-13 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
CN120265630A (zh) * 2022-11-02 2025-07-04 Ac免疫有限公司 用于诊断tdp-43蛋白质病的新化合物
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
KR20060103265A (ko) * 2003-12-19 2006-09-28 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비시클릭 헤테로사이클
HRP20100298T1 (hr) * 2004-08-26 2010-06-30 Pfizer Inc. Enantiomerno čisti aminoheteroarilni spojevi kao inhibitori proteinskih kinaza
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
EA016300B1 (ru) * 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
AU2007224659A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic NF-KB inhibitors
JP2010510177A (ja) * 2006-11-17 2010-04-02 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害を治療するための化合物および方法
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US20120202787A1 (en) * 2009-10-20 2012-08-09 Pfizer Inc. Novel Heteroaryl Imidazoles And Heteroaryl Triazoles As Gamma-Secretase Modulators
WO2011084642A1 (en) * 2009-12-16 2011-07-14 Neuropore Therapies, Inc. Compound suitable for the treatment of synucleopathies
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
HK1202452A1 (en) 2012-03-28 2015-10-02 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
JP2015522617A (ja) 2012-07-16 2015-08-06 ニューロポア セラピーズ，インコーポレイティド タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体
RS60547B1 (sr) 2014-01-29 2020-08-31 UCB Biopharma SRL Heteroaril amidi kao inhibitori proteinske agregacije
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
AU2018212436A1 (en) 2017-01-26 2019-07-25 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
EP3573986B1 (en) 2017-01-26 2021-05-26 UCB Biopharma SRL Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation

Also Published As

Publication number Publication date
AP2016009347A0 (en) 2016-07-31
JP6619741B2 (ja) 2019-12-11
KR20160113287A (ko) 2016-09-28
CN106132960B (zh) 2019-12-17
CN111039939B (zh) 2023-09-19
IL246987B (en) 2021-12-01
PH12016501493A1 (en) 2017-02-06
CY1123374T1 (el) 2021-12-31
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
EP3099684A1 (en) 2016-12-07
CN106132960A (zh) 2016-11-16
EA201691529A1 (ru) 2017-01-30
MX2016009896A (es) 2017-01-11
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
ME03800B (me) 2021-04-20
TR201809440T4 (tr) 2018-07-23
SMT202000376T1 (it) 2020-09-10
CA2937967A1 (en) 2015-08-06
ES2675301T3 (es) 2018-07-10
JP6783900B2 (ja) 2020-11-11
SI3348556T1 (sl) 2020-10-30
PL3348556T3 (pl) 2020-11-02
HRP20180813T1 (hr) 2018-07-27
LT3099684T (lt) 2018-06-25
NZ722487A (en) 2022-04-29
SG11201606108RA (en) 2016-08-30
BR112016017344B1 (pt) 2023-05-16
DK3348556T3 (da) 2020-08-03
SMT201800318T1 (it) 2018-07-17
AU2015211119A1 (en) 2016-08-11
PT3348556T (pt) 2020-07-27
HRP20201107T1 (hr) 2020-10-30
ZA201605246B (en) 2022-05-25
PE20161393A1 (es) 2017-01-08
PT3099684T (pt) 2018-10-22
MY187450A (en) 2021-09-22
RS57533B1 (sr) 2018-10-31
BR112016017344A2 (pt) 2017-10-03
IL246987A0 (en) 2016-09-29
BR122018001892B1 (pt) 2023-05-02
CA2937967C (en) 2022-07-26
HRP20201107T8 (hr) 2020-12-11
JP2017505779A (ja) 2017-02-23
CL2016001918A1 (es) 2017-01-13
US20190308965A1 (en) 2019-10-10
LT3348556T (lt) 2020-08-10
CR20160394A (es) 2016-11-01
KR102383038B1 (ko) 2022-04-05
EP3099684B1 (en) 2018-04-04
AU2015211119A8 (en) 2016-12-15
AU2015211119B2 (en) 2019-05-30
SA516371579B1 (ar) 2019-07-16
CN111039939A (zh) 2020-04-21
PL3099684T3 (pl) 2018-09-28
EP3348556A1 (en) 2018-07-18
EA032374B1 (ru) 2019-05-31
JP2019163321A (ja) 2019-09-26
WO2015116663A8 (en) 2016-09-15
SI3099684T1 (en) 2018-08-31
DK3099684T3 (en) 2018-07-16
HK1231470A1 (zh) 2017-12-22
HUE050964T2 (hu) 2021-01-28
EP3348556B1 (en) 2020-04-29
US11078196B2 (en) 2021-08-03
EP3099684B8 (en) 2018-07-04
US20180093979A1 (en) 2018-04-05
RS60547B1 (sr) 2020-08-31
ECSP16070327A (es) 2018-05-31
HUE040274T2 (hu) 2019-03-28
ES2808978T8 (es) 2021-03-22
ES2808978T3 (es) 2021-03-02
PH12016501493B1 (en) 2017-02-06
US20160207912A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
CY1120348T1 (el) Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1120361T1 (el) Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido)
EA201990221A1 (ru) 1,3-дигидроксифенильные производные, применимые в качестве иммуномодуляторов
ME03487B (me) Kompozicije koje sadrže blautia bakterijske sojeve za liječenje visceralne hipersenzitivnosti
EA201691857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX373373B (es) Inhibidores de desmetilasa-1 específica de lisina.
PH12015502028A1 (en) Ido inhibitors
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX373549B (es) Derivado de pirazol amida.
MX378155B (es) Derivados de 9h-pirrolo-dipiridina.
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MX2019007053A (es) Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
EP3359521C0 (en) NEW COMPOUNDS FOR THE TREATMENT OF MITOCHONDRIAL DISEASE
BR112015001096A2 (pt) derivados de di e tri-heteroaril como inibidores de agregação de proteína
EP3449001A4 (en) INHIBITION OF MIR-22-MIRNA BY APT-110
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
BR112016022575A2 (pt) Composições e métodos para o tratamento de doenças neurodegenerativas
MX2019007054A (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CY1124509T1 (el) Ν,ν-δις-2-μερκαπτοαιθυλο ισοφθαλαμιδιο για τη θεραπεια της νοσου toy parkinson
EA201992022A1 (ru) Терапевтическая рнк